TransMedics Group, Inc. (NASDAQ:TMDX) Holdings Raised by HB Wealth Management LLC

Key Points

• HB Wealth Management LLC increased its stake in TransMedics Group, Inc. by 30.4%, acquiring a total of 10,627 shares valued at $715,000.
• TransMedics reported a quarterly earnings per share of $0.92, significantly exceeding analysts' expectations of $0.48, alongside revenue growth of 37.7% year-over-year.
• Multiple analysts have upgraded their price targets for TransMedics Group, with Piper Sandler setting a new target of $145.00, reflecting increased confidence in the company's performance.

HB Wealth Management LLC grew its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 30.4% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,627 shares of the company's stock after buying an additional 2,478 shares during the quarter. HB Wealth Management LLC's holdings in TransMedics Group were worth $715,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Commonwealth Equity Services LLC grew its stake in TransMedics Group by 17.3% in the fourth quarter. Commonwealth Equity Services LLC now owns 9,905 shares of the company's stock worth $618,000 after purchasing an additional 1,460 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in TransMedics Group in the fourth quarter worth approximately $399,000. LPL Financial LLC grew its stake in TransMedics Group by 24.7% in the fourth quarter. LPL Financial LLC now owns 26,386 shares of the company's stock worth $1,645,000 after purchasing an additional 5,223 shares in the last quarter. Vanguard Group Inc. grew its stake in TransMedics Group by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock worth $226,700,000 after purchasing an additional 40,860 shares in the last quarter. Finally, Prudential Financial Inc. grew its stake in TransMedics Group by 1,023.2% in the fourth quarter. Prudential Financial Inc. now owns 34,056 shares of the company's stock worth $2,123,000 after purchasing an additional 31,024 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

TransMedics Group Stock Up 1.3%

Shares of TMDX stock traded up $1.58 on Friday, reaching $120.55. 1,775,224 shares of the stock were exchanged, compared to its average volume of 1,198,309. The company has a current ratio of 9.86, a quick ratio of 8.32 and a debt-to-equity ratio of 1.61. The business's 50 day moving average price is $124.51 and its 200 day moving average price is $95.00. The company has a market capitalization of $4.11 billion, a price-to-earnings ratio of 62.46 and a beta of 2.09. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. During the same quarter in the prior year, the firm posted $0.35 earnings per share. TransMedics Group's revenue for the quarter was up 37.7% on a year-over-year basis. As a group, sell-side analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Oppenheimer increased their target price on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research report on Tuesday, June 17th. Morgan Stanley raised their price objective on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research report on Friday. Canaccord Genuity Group raised their price objective on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday, July 15th. Piper Sandler reissued an "overweight" rating and issued a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Finally, Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, TransMedics Group presently has a consensus rating of "Moderate Buy" and an average target price of $129.11.

Insider Buying and Selling

In other news, Director Edward M. Basile sold 6,000 shares of TransMedics Group stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the completion of the sale, the director directly owned 732 shares in the company, valued at approximately $84,641.16. This trade represents a 89.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David Weill sold 732 shares of TransMedics Group stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total transaction of $90,680.16. Following the sale, the director owned 12,134 shares of the company's stock, valued at approximately $1,503,159.92. The trade was a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,418 shares of company stock valued at $1,512,613 over the last quarter. 7.00% of the stock is currently owned by insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.